The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: An open label preliminary study

International Clinical Psychopharmacology

Volumn 20, Issue 1, 2005, Pages 23-25

  Gross Isseroff, Ruth ^a,b   Magen, Ayelet ^a   Shiloh, Roni ^a,b   Hermesh, Haggai ^a,b   Weizman, Abraham ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Neuroleptic induced akathisia; Zolmitriptan

Indexed keywords

BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERPHENAZINE; PROPRANOLOL; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 2 ANTAGONIST; TRIHEXYPHENIDYL; ZOLMITRIPTAN; OXAZOLIDINONE DERIVATIVE; SEROTONIN; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; OPEN STUDY; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; CLINICAL TRIAL; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEROTONIN; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 12144263426     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200501000-00005     Document Type: Article

References (20)

1. Ananth J, Lin KM (1986). Propranolol in psychiatry. Therapeutic uses and side effects. Neuropsychobiology 15:20-27.
2. Barnes TRE (1989). A rating scale for drug induced akathisia. Br J Psychiatry 154:672-676.
3. Casey DE (2004). Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65:25-28.
4. Dahlof C (2003). Clinical applications of new therapeutic deliveries in migraine. Neurology 61:S31-S34.
5. Dobson CF, Tohyama Y, Diksic M, Hamel E (2004). Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 24:2-11.
6. Dodick DW, Martin V (2004). Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 24:417-424.
7. Dowson AJ, Charlesworth BR, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M (2003). Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 17:839-851.
8. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A (2001). Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 21:612-615.
9. Fleischhacker WW, Roth SD, Kane JM (1990). The pharmacologic treatment of neuroptic induced akathisia. J Clin Psychopharmacol 10:12-21.
10. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
11. Lader M (1988). Beta-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 49:213-223.
12. Millson DS, Tepper SJ, Rapoport AM (2000). Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother 1:391-404.
13. Poyurovsky M, Weizman A (2001). Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 179:4-8.
14. 2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 174:238-242.
15. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A (2003). Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 23:305-308.
16. Reuter U, Salomone S, lckenstein GW, Waeber C (2004). Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia 24:398-407.
17. Sachdev P, Loneragan MA (1991). The present status of akathisia. J Nerv Ment Dis 179:381-391.
18. Stryjer R, Strous RD, Bar F (2003). Treatment of neuroleptic-induced akathisia with the 5-HT2 A antagonist trazodone. Clin Neuropharmacol 26:137-141.
19. Tepper SJ, Rapoport AM, Sheftell FD (2002). Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084-1088.
20. Tuchman M, Edvinsson L, Geraud G, Korczyn A, Mauskop A, Pfaffenrath V (1999). Zolmitriptan provides consistent migraine relief when used in the long-term. Curr Med Res Opin 15:272-281.